Cargando…
Treatment with the direct oral anticoagulants (DOACs) Apixaban and Rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD)
OBJECTIVE: To demonstrate the increasing evidence for an aetiological role of cerebral mitochondrial dysfunction in neuropsychiatric disorders. To raise awareness of the importance of frontline staff partaking in post marketing surveillance of medications. CASE REPORT: We report the cases of two pat...
Autores principales: | Porter, Kim, Souza, Stephen De, Hargreaves, Iain, Goddard, Rebecca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769226/ http://dx.doi.org/10.1192/bjo.2021.346 |
Ejemplares similares
-
Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD)
por: Porter, Kim Maria Frances, et al.
Publicado: (2021) -
DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa
(Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022) -
Developing Inpatient Management Strategies for Behavioural and Psychological Symptoms of Dementia (DIMS-BPSD)
por: Parker, Jennifer, et al.
Publicado: (2022) -
Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the
Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
por: Slavik, L., et al.
Publicado: (2019) -
Assessment of DOAC in GEriatrics (
Adage
Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients
por: Foulon-Pinto, Geoffrey, et al.
Publicado: (2023)